AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35225542 — intervention group
Group type: COMPARATOR
Intervention: Vitrectomy with standard ILM peeling (Group A)
Number of subjects: 150
Study 32918907 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced aerobic exercise and upper extremity repetitive task practice (FE+RTP) [n=16]
Number of subjects: 43
Study 32918907 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary aerobic exercise and upper extremity repetitive task practice (VE+RTP) [n=14]
Number of subjects: 43
Study 32918907 — intervention group
Group type: COMPARATOR
Intervention: Non-aerobic control group [n=13]
Number of subjects: 43
Study 36404687 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined agent flurbiprofen 8.75 mg and cetylpyridinium chloride 1.0 mg in the form of tablets for resorption
Number of subjects: 266
Study 36404687 — intervention group
Group type: COMPARATOR
Intervention: Cetylpyridinium chloride 1.2 mg in the form of medicinal lozenges
Number of subjects: 266
Study 33491594 — intervention group
Group type: EXPERIMENTAL
Intervention: β-alanine supplementation (6.4 g·d-1) for 28 days
Number of subjects: 19
Study 33491594 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (PLA)
Number of subjects: 19
Study 33491594 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (BA and PLA)
Number of subjects: 19
Study 32250301 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 11
Study 32250301 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep control
Number of subjects: 11
Study 36014880 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-soluble tomato concentrate (WSTC)
Number of subjects: 52
Study 34336888 — intervention group
Group type: EXPERIMENTAL
Intervention: 577‐nm subthreshold micropulse laser (SML)
Number of subjects: 110
Study 34336888 — intervention group
Group type: COMPARATOR
Intervention: 577‐nm conventional laser (CL)
Number of subjects: 110
Study 34281854 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid (ZA)
Number of subjects: 0
Study 34281854 — intervention group
Group type: EXPERIMENTAL
Intervention: RANKL inhibitors (RANKL-I)
Number of subjects: 0
Study 33506810 — intervention group
Group type: EXPERIMENTAL
Intervention: Early low-molecular-weight heparin (LMWH) administration within 7 days from COVID-19 signs and symptoms onset
Number of subjects: 93
Study 33506810 — intervention group
Group type: COMPARATOR
Intervention: Delayed low-molecular-weight heparin (LMWH) administration after 7 days
Number of subjects: 93
Study 33506810 — intervention group
Group type: EXPERIMENTAL
Intervention: Early low-molecular-weight heparin (LMWH) administration
Number of subjects: 93
Study 33595663 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated diastolic blood pressure less than 60 mm Hg
Number of subjects: 7515
Study 33595663 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure between 70 and 80 mm Hg
Number of subjects: 7515
Study 33811776 — intervention group
Group type: EXPERIMENTAL
Intervention: Adsorbent lotion containing tapioca starch, spent grain wax, Butyrospermum parkii extract, argania spinosa kernel oil, aloe barbadensis, rosehip oil, and allantoin applied twice daily.
Number of subjects: 40
Study 33811776 — intervention group
Group type: EXPERIMENTAL
Intervention: Adsorbent lotion
Number of subjects: 40
Study 33811776 — intervention group
Group type: COMPARATOR
Intervention: 1% hydrocortisone cream applied twice daily.
Number of subjects: 40
Study 33811776 — intervention group
Group type: COMPARATOR
Intervention: Adsorbent lotion and 1% hydrocortisone cream
Number of subjects: 40
Study 34238698 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocauterization after removal of apocrine sweat glands
Number of subjects: 90
Study 34238698 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided BOTOX injection
Number of subjects: 90
Study 34238698 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocauterization after removal of apocrine sweat glands followed by ultrasound-guided BOTOX injection after two weeks
Number of subjects: 90
Study 32481441 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil 1.78 µg/kg (group S)
Number of subjects: 60
Study 32481441 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine 1.78 mg/kg (group N)
Number of subjects: 60
Study 36412288 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer injury prevention education group (intervention group)
Number of subjects: 502
Study 36412288 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 502
Study 34911901 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI‐plus (pulmonary vein isolation plus extensive ablation strategy)
Number of subjects: 497
Study 34911901 — intervention group
Group type: COMPARATOR
Intervention: PVI‐alone (pulmonary vein isolation only)
Number of subjects: 497
Study 32045638 — intervention group
Group type: EXPERIMENTAL
Intervention: HES50 (50 mg kg‐1 hesperidin)
Number of subjects: 900
Study 32045638 — intervention group
Group type: EXPERIMENTAL
Intervention: HES75 (75 mg kg‐1 hesperidin)
Number of subjects: 900
Study 32045638 — intervention group
Group type: EXPERIMENTAL
Intervention: HES100 (100 mg kg‐1 hesperidin)
Number of subjects: 900
Study 32045638 — intervention group
Group type: EXPERIMENTAL
Intervention: HES150 (150 mg kg‐1 hesperidin)
Number of subjects: 900
Study 32045638 — intervention group
Group type: EXPERIMENTAL
Intervention: HES50-150 (50-150 mg kg‐1 hesperidin)
Number of subjects: 900
Study 32045638 — intervention group
Group type: COMPARATOR
Intervention: Control (basal diet)
Number of subjects: 900
Study 32352832 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based training (MBT)
Number of subjects: 61
Study 32352832 — intervention group
Group type: COMPARATOR
Intervention: Adaptive cognitive training (aCT)
Number of subjects: 61
Study 32352832 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (WL) control
Number of subjects: 61
Study 36214729 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-containing mouthwash
Number of subjects: 35
Study 36214729 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 35
Study 34433653 — intervention group
Group type: EXPERIMENTAL
Intervention: Spartalizumab (400 mg once every 4 weeks)
Number of subjects: 122
Study 34433653 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (per investigator's choice)
Number of subjects: 122
Study 32105221 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% HF for 30 seconds (HF5-30)
Number of subjects: 91
Study 32105221 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% HF for 60 seconds (HF5-60)
Number of subjects: 91
Study 32105221 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% HF for 90 seconds (HF5-90)
Number of subjects: 91
Study 32105221 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% HF for 30 seconds (HF10-30)
Number of subjects: 91
Study 32105221 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% HF for 60 seconds (HF10-60)
Number of subjects: 91
Study 32105221 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% HF for 90 seconds (HF10-90)
Number of subjects: 91
Study 32105221 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 91
Study 631198356 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering treatment
Number of subjects: 1000
Study 631198356 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure lowering treatment
Number of subjects: 1000
Study 35277055 — intervention group
Group type: EXPERIMENTAL
Intervention: Early introduction of standardized complementary food (10–12 weeks of life)
Number of subjects: 177
Study 35277055 — intervention group
Group type: COMPARATOR
Intervention: Late introduction of standardized complementary food (16–18 weeks of life)
Number of subjects: 177
Study 34195767 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectoral nerve block
Number of subjects: 73
Study 34195767 — intervention group
Group type: COMPARATOR
Intervention: Control (no pectoral nerve block)
Number of subjects: 73
Study 32052249 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 0
Study 32052249 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35998002 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality (IVR) during IV blood draw
Number of subjects: 59
Study 35998002 — intervention group
Group type: COMPARATOR
Intervention: Standard practice during IV blood draw
Number of subjects: 59
Study 34329196 — intervention group
Group type: EXPERIMENTAL
Intervention: >0-0.5 servings/week
Number of subjects: 91891
Study 34329196 — intervention group
Group type: EXPERIMENTAL
Intervention: >0.5-1 serving/week
Number of subjects: 91891
Study 34329196 — intervention group
Group type: EXPERIMENTAL
Intervention: >1-2 servings/week
Number of subjects: 91891
Study 34329196 — intervention group
Group type: EXPERIMENTAL
Intervention: >2 servings/week
Number of subjects: 91891
Study 34329196 — intervention group
Group type: COMPARATOR
Intervention: Chocolate consumption
Number of subjects: 91891
Study 32917369 — intervention group
Group type: EXPERIMENTAL
Intervention: PM2.5 exposure
Number of subjects: 5028
Study 32917369 — intervention group
Group type: EXPERIMENTAL
Intervention: PM10 exposure
Number of subjects: 5028
Study 32917369 — intervention group
Group type: EXPERIMENTAL
Intervention: SO2 exposure
Number of subjects: 5028
Study 32917369 — intervention group
Group type: EXPERIMENTAL
Intervention: O3 exposure
Number of subjects: 5028
Study 35077474 — intervention group
Group type: EXPERIMENTAL
Intervention: rasagiline (monotherapy)
Number of subjects: 2
Study 34337284 — intervention group
Group type: EXPERIMENTAL
Intervention: ATTUNE knee implant system
Number of subjects: 150
Study 34337284 — intervention group
Group type: COMPARATOR
Intervention: P.F.C. SIGMA knee implant system
Number of subjects: 150
Study 34987324 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling with conventional therapy
Number of subjects: 36
Study 34987324 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural mobilization with conventional therapy
Number of subjects: 36
Study 34011163 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG with complete revascularization (CR)
Number of subjects: 0
Study 34011163 — intervention group
Group type: COMPARATOR
Intervention: CABG with incomplete revascularization (IR)
Number of subjects: 0
Study 34011163 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI with complete revascularization (CR)
Number of subjects: 0
Study 34011163 — intervention group
Group type: COMPARATOR
Intervention: PCI with incomplete revascularization (IR)
Number of subjects: 0
Study 34011163 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI with rSS=0
Number of subjects: 0
Study 34011163 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI with rSS>0-4
Number of subjects: 0
Study 34011163 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI with rSS>4-8
Number of subjects: 0
Study 34011163 — intervention group
Group type: COMPARATOR
Intervention: PCI with rSS>8
Number of subjects: 0
Study 32966163 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy scales related to speech, social, emotional, and cognitive components of stuttering.
Number of subjects: 320
Study 32966163 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported success in treatment, beliefs about the importance of multidimensional treatment, and self-reported empathy.
Number of subjects: 320
Study 32966163 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic and clinical training in fluency disorders.
Number of subjects: 320
Study 35875033 — intervention group
Group type: EXPERIMENTAL
Intervention: Special day for men
Number of subjects: 0
Study 35875033 — intervention group
Group type: EXPERIMENTAL
Intervention: Deployment of male champions
Number of subjects: 0
Study 35875033 — intervention group
Group type: COMPARATOR
Intervention: Incentive (food package) for couples
Number of subjects: 0
Study 33229928 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein B measurement
Number of subjects: 0
Study 33229928 — intervention group
Group type: COMPARATOR
Intervention: Conventional lipid markers (total cholesterol, triglycerides, LDL-cholesterol, non-HDL-cholesterol)
Number of subjects: 0
Study 35239707 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea making training (5 sessions of 1 hour each)
Number of subjects: 25
Study 35239707 — intervention group
Group type: COMPARATOR
Intervention: Stepping training (5 sessions of 1 hour each)
Number of subjects: 25
Study 33277162 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative carbohydrate drinks
Number of subjects: 184
Study 33277162 — intervention group
Group type: COMPARATOR
Intervention: Standard care (fasting from midnight with free clear fluids until two hours prior to surgery)
Number of subjects: 184
Study 35932067 — intervention group
Group type: EXPERIMENTAL
Intervention: Transport PLUS intervention (administered by trained EMTs)
Number of subjects: 439
Study 35931131 — intervention group
Group type: COMPARATOR
Intervention: Vaginal hysterectomy with uterosacral ligament suspension (USLS)
Number of subjects: 173
Study 35931131 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase of 5 kg/m2 in BMI
Number of subjects: 173
Study 35931131 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase of 1 year in duration of prolapse symptoms
Number of subjects: 173
Study 35931131 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with >5 years of prolapse symptoms
Number of subjects: 173
Study 35931131 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who are obese and overweight
Number of subjects: 173
Study 32610266 — intervention group
Group type: EXPERIMENTAL
Intervention: IN.PACT Admiral DCB
Number of subjects: 1980
Study 32610266 — intervention group
Group type: COMPARATOR
Intervention: PTA
Number of subjects: 1980
Study 32610266 — intervention group
Group type: EXPERIMENTAL
Intervention: IN.PACT Admiral DCB (broader use)
Number of subjects: 1980
Study 34791269 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant cryoablation during mitral valve surgery
Number of subjects: 242
Study 32777032 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of clinicians' antibiotic prescribing rate (80.2%)
Number of subjects: 232256
Study 32777032 — intervention group
Group type: COMPARATOR
Intervention: Lowest quartile of clinicians' antibiotic prescribing rate (42.1%)
Number of subjects: 232256
Study 32777032 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients seen by the highest-prescribing clinicians
Number of subjects: 232256
Study 35263558 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihistamine-releasing contact lens (etafilcon A with 0.019 mg ketotifen)
Number of subjects: 560
Study 35263558 — intervention group
Group type: COMPARATOR
Intervention: Placebo contact lens (etafilcon A with no added drug)
Number of subjects: 560
Study 35263558 — intervention group
Group type: EXPERIMENTAL
Intervention: Both test and placebo lenses
Number of subjects: 560
Study 34396402 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology Enhanced Community Health Precision Nursing (TECH-PN) intervention with unlimited precision care services driven by interim STI and macrolide resistance testing results.
Number of subjects: 76
Study 34396402 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving 1 community nursing visit with self-management for interim care per national guidelines.
Number of subjects: 76
Study 34396402 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline laboratory results for STI assessment.
Number of subjects: 76
Study 32730798 — intervention group
Group type: EXPERIMENTAL
Intervention: Osilodrostat (1–30 mg twice daily)
Number of subjects: 137
Study 32730798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 32730798 — intervention group
Group type: EXPERIMENTAL
Intervention: Osilodrostat
Number of subjects: 137
Study 35789381 — intervention group
Group type: EXPERIMENTAL
Intervention: SER-109 (investigational oral microbiome therapeutic)
Number of subjects: 182
Study 35789381 — intervention group
Group type: EXPERIMENTAL
Intervention: Cdiff32 questionnaire
Number of subjects: 182
Study 34293010 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTA)
Number of subjects: 1405
Study 34293010 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BTA)
Number of subjects: 1405
Study 35379626 — intervention group
Group type: EXPERIMENTAL
Intervention: SUCCESS stop smoking strategy delivered by trained practice assistants after cervical smear
Number of subjects: 0
Study 35379626 — intervention group
Group type: COMPARATOR
Intervention: Usual care condition
Number of subjects: 0
Study 35379626 — intervention group
Group type: EXPERIMENTAL
Intervention: SUCCESS stop smoking strategy
Number of subjects: 0
Study 34749808 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium polyP microparticles (Ca‐polyP MPs) only
Number of subjects: 8
Study 34749808 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Calcium polyP microparticles (Ca‐polyP MPs) and biphasic calcium phosphate (BCP)
Number of subjects: 8
Study 35109953 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin, mineral and n-3 polyunsaturated fatty acid supplementation
Number of subjects: 176
Study 35109953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 34171709 — intervention group
Group type: EXPERIMENTAL
Intervention: PresStim group (Dynamic RTPS and NS set at 1.5 mA then decreased; n = 50)
Number of subjects: 100
Study 34171709 — intervention group
Group type: COMPARATOR
Intervention: Control group (fixed thresholds for in‐line pressure mechanical manometer and NS at 0.2 mA; n = 50)
Number of subjects: 100
Study 34171709 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 35258510 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 51
Study 35258510 — intervention group
Group type: EXPERIMENTAL
Intervention: GEM/nab-PTX
Number of subjects: 51
Study 35258510 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 51
Study 32493434 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based interactive youth educational program alone (Group A)
Number of subjects: 1979
Study 32493434 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based interactive youth educational program followed by an Internet-based booster (Group B)
Number of subjects: 1979
Study 32493434 — intervention group
Group type: COMPARATOR
Intervention: No-interaction control (Group C)
Number of subjects: 1979
Study 36275772 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 µg bivalent NoV vaccine
Number of subjects: 60
Study 36275772 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 µg bivalent NoV vaccine
Number of subjects: 60
Study 36275772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 36275772 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dose levels of the vaccine
Number of subjects: 60
Study 34224213 — intervention group
Group type: COMPARATOR
Intervention: Probiotics
Number of subjects: 1659
Study 34224213 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotics
Number of subjects: 1659
Study 34224213 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics
Number of subjects: 1659
Study 35559854 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized normative feedback (PNF) on alcohol use and coping
Number of subjects: 499
Study 35559854 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized normative feedback (PNF) on alcohol use only
Number of subjects: 499
Study 35559854 — intervention group
Group type: COMPARATOR
Intervention: Control topics
Number of subjects: 499
Study 32902905 — intervention group
Group type: EXPERIMENTAL
Intervention: Five SMS per week
Number of subjects: 3994
Study 32902905 — intervention group
Group type: EXPERIMENTAL
Intervention: Three SMS per week
Number of subjects: 3994
Study 32902905 — intervention group
Group type: COMPARATOR
Intervention: Zero SMS per week
Number of subjects: 3994
Study 32902905 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face consultation with a diabetes educator
Number of subjects: 3994
Study 32902905 — intervention group
Group type: EXPERIMENTAL
Intervention: Call from a dietitian
Number of subjects: 3994
Study 32902905 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrolled with pharmacists
Number of subjects: 3994
Study 35875694 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 IU (30 µg) capsules of vitamin D3 once per day
Number of subjects: 53
Study 35875694 — intervention group
Group type: COMPARATOR
Intervention: Placebo oil capsules once per day
Number of subjects: 53
Study 35875694 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 53
Study 32412388 — intervention group
Group type: EXPERIMENTAL
Intervention: Working Alliance Inventory short-form (WAI-S)
Number of subjects: 338
Study 32130806 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting cabotegravir plus rilpivirine
Number of subjects: 566
Study 32130806 — intervention group
Group type: COMPARATOR
Intervention: Oral therapy with dolutegravir-abacavir-lamivudine
Number of subjects: 566
Study 34941354 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPS‐5 (Clinician‐Administered PTSD Scale for DSM‐5)
Number of subjects: 198
Study 34941354 — intervention group
Group type: EXPERIMENTAL
Intervention: PCL‐5 (PTSD Checklist for DSM‐5)
Number of subjects: 198
Study 34941354 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliable or clinically significant change (CSC)
Number of subjects: 198
Study 32264972 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab
Number of subjects: 0
Study 32264972 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study 35379189 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate neuromuscular blockade combined with transverse abdominal plane block (M group)
Number of subjects: 80
Study 35379189 — intervention group
Group type: COMPARATOR
Intervention: Deep neuromuscular blockade (D group)
Number of subjects: 80
Study 34352845 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (transcutaneous electrical nerve stimulation)
Number of subjects: 109
Study 34352845 — intervention group
Group type: COMPARATOR
Intervention: IV sedation (fentanyl, midazolam)
Number of subjects: 109
Study 34352845 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician perception of pain in TENS group
Number of subjects: 109
Study 34352845 — intervention group
Group type: COMPARATOR
Intervention: Physician perception of pain in IV group
Number of subjects: 109
Study 35764205 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (≥1,000 IU/day for ≥4 days/week)
Number of subjects: 236